Obstetrics & Gynecology Doctors in Carlsbad, NM Accepting Medicare

5 Obstetrics & Gynecology doctors found. Showing 1 - 5

Dr. Mario Toledo-couret, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2420 W Pierce St Ste 105, Carlsbad, NM 88220 Phone: 575-628-8852    Fax: 575-628-8856

Richard Adams, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 2420 W Pierce St, Ste 200, Carlsbad, NM 88220 Phone: 505-885-0995

Dr. Ram K Pai, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 2420 W Pierce St, Suite 104, Carlsbad, NM 88220 Phone: 505-887-5528    Fax: 505-885-3566

Brooke Ainsley Huffsmith, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2430 W Pierce St, Carlsbad, NM 88220 Phone: 575-887-4100

Dr. Stephen Schneberger, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 2420 W Pierce St, Suite 200, Carlsbad, NM 88220 Phone: 575-885-0995    Fax: 575-885-0870

News Archive

Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

The tyrosine kinase inhibitor afatinib significantly improved progression-free survival compared to methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy, the results of a phase III trial show.

DKMS teams up with football clubs to raise awareness of blood stem cell donation

Blood cancer charity DKMS is teaming up with football clubs up and down the country in a bid to raise awareness of blood stem cell donation and to register donors. Football Vs Blood Cancer is a new campaign being run by DKMS following support from clubs such as Everton.

Teva Pharmaceutical Industries to acquire ratiopharm for €3.625 billion

Teva Pharmaceutical Industries Ltd. announced today that it has entered into a definitive agreement to acquire ratiopharm, Germany's second largest generics producer and the sixth largest generic drug company worldwide, for an enterprise value of €3.625 billion. The transaction is subject to certain conditions including relevant regulatory approvals. On a pro forma basis, the combined company would have had 2009 revenues of $16.2 billion. Teva expects to complete the transaction by year-end 2010.

Study explores obstacles to treating opioid use disorder with an effective medication

In an effort to find ways to improve long-term outcomes for people with opioid use disorder, University of Massachusetts Amherst epidemiology researcher Elizabeth Evans set out to study the obstacles to treating this chronic condition with an effective medication, buprenorphine-naloxone.

Achievement of tenth milestone triggers EUR 2.5 million payment from Boehringer Ingelheim to Evotec

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone, triggering a payment of EUR 2.5 million to Evotec. The milestone reached was the selection of a candidate compound for pre-development studies in an inflammation and immunology programme.

Read more Medical News

› Verified 4 days ago